Sean Scanlan - Jan 3, 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
SVP, Marketing
Signature
/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Stock symbol
TMCI
Transactions as of
Jan 3, 2022
Transactions value $
-$42,428
Form type
4
Date filed
1/5/2022, 07:57 PM
Previous filing
Nov 12, 2021
Next filing
Jan 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Options Exercise $1.57K +1K $1.57* 1K Jan 3, 2022 Direct F1
transaction TMCI Common Stock Sale -$20K -1K -100% $20.02 0 Jan 3, 2022 Direct F1, F2
transaction TMCI Common Stock Options Exercise $785 +500 $1.57* 500 Jan 4, 2022 Direct F1
transaction TMCI Common Stock Sale -$10K -500 -100% $20.00 0 Jan 4, 2022 Direct F1
transaction TMCI Common Stock Options Exercise $1.26K +800 $1.57* 800 Jan 5, 2022 Direct F1
transaction TMCI Common Stock Sale -$16K -800 -100% $20.02 0 Jan 5, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Options Exercise $0 -1K -1.74% $0.00 56.5K Jan 3, 2022 Common Stock 1K $1.57 Direct F1, F4
transaction TMCI Stock Option (Right to Buy) Options Exercise $0 -500 -0.88% $0.00 56K Jan 4, 2022 Common Stock 500 $1.57 Direct F1, F4
transaction TMCI Stock Option (Right to Buy) Options Exercise $0 -800 -1.43% $0.00 55.2K Jan 5, 2022 Common Stock 800 $1.57 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.06 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option is partially vested and will vest with respect to the remaining shares in equal annual installments, so that the options will be fully vested on April 23, 2023.